SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

PCI-29732

Item No. 29036



CAS Registry No.:	330786-25-9
Formal Name:	1-cyclopentyl-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
MF:	$C_{22}H_{21}N_5O$
FW:	371.4
Purity:	≥98%
UV/Vis.:	λ_{max}: 262, 289 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

PCI-29732 is supplied as a crystalline solid. A stock solution may be made by dissolving the PCI-29732 in the solvent of choice, which should be purged with an inert gas. PCI-29732 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of PCI-29732 in these solvents is approximately 5, 10, and 20 mg/ml, respectively.

PCI-29732 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, PCI-29732 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. PCI-29732 has a solubility of approximately 0.3 mg/ml in a 1:2 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

PCI-29732 is a multi-kinase inhibitor.[1] It inhibits the Tec family kinase BTK and the Src family kinases LCK and LYN (K_is = 8.2, 4.6, and 2.5 nM, respectively), as well as the activity of three receptor tyrosine kinases and seven non-receptor tyrosine kinases by greater than 90% in a panel of over 100 kinases at 10 µM. PCI-29732 inhibits calcium flux in Ramos B cells and phosphorylation of phospholipase Cγ1 (PLCγ1) with IC_{50} values of 0.53 and 0.33 µM, respectively. It is cytotoxic to S1-MI-80, H460/MX20, and KBv200 cancer cells overexpressing the ATP-binding cassette transporter (IC_{50}s = 7.8, 6.3, and 6.02 µM, respectively).[2] PCI-29732 (20 mg/kg), in combination with the DNA topoisomerase I inhibitor topotecan (Item No. 14129), reduces tumor growth in an H460/MX20 mouse xenograft model.

References

1. Pan, Z., Scheerens, H., Li, S.J., *et al.* Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. *ChemMedChem* **2(1),** 58-61 (2007).
2. Ge, C., Wang, F., Ciu, C., *et al.* PCI29732, a Bruton's tyrosine kinase inhibitor, enhanced the efficacy of conventional chemotherapeutic agents in ABCG2-overexpressing cancer cells. *Cell. Physiol. Biochem.* **48(6),** 2302-2317 (2018).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM